This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
by Zacks Equity Research
Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
by Kinjel Shah
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
by Kinjel Shah
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
by Zacks Equity Research
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
by Zacks Equity Research
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
by Zacks Equity Research
Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
by Zacks Equity Research
Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
by Kinjel Shah
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
by Zacks Equity Research
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
by Zacks Equity Research
AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
by Zacks Equity Research
Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
by Zacks Equity Research
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
by Zacks Equity Research
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
by Zacks Equity Research
The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
by Zacks Equity Research
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
by Zacks Equity Research
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
by Zacks Equity Research
GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
by Zacks Equity Research
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.